Stockscreener 앱 받기
6.695
1.13%
0.085
전일 마감가:
$6.61
열려 있는:
$6.57
하루 거래량:
352.71K
Relative Volume:
0.14
시가총액:
$528.45M
수익:
$311.71M
순이익/손실:
$163.05M
주가수익비율:
3.3753
EPS:
1.9835
순현금흐름:
$172.79M
1주 성능:
+6.11%
1개월 성능:
-9.05%
6개월 성능:
-40.84%
1년 성능:
-6.63%
1일 변동 폭
$6.502
$6.762
1주일 범위
$6.1635
$6.762
52주 변동 폭
$5.60
$17.43
CorMedix Inc Stock (CRMD) Company Profile
명칭
CorMedix Inc
전화
908-517-9500
주소
400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ
Compare CRMD vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRMD
CorMedix Inc
|
6.685 | 522.52M | 311.71M | 163.05M | 172.79M | 1.9835 |
VRTX
Vertex Pharmaceuticals Inc
|
456.24 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
758.59 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.19 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.80 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.85 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
CorMedix Inc Stock (CRMD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 업그레이드 | D. Boral Capital | Hold → Buy |
| 2025-06-30 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2025-06-30 | 개시 | H.C. Wainwright | Buy |
| 2025-03-07 | 개시 | Leerink Partners | Outperform |
| 2025-01-13 | 개시 | D. Boral Capital | Buy |
| 2024-08-26 | 개시 | Rodman & Renshaw | Buy |
| 2023-08-10 | 개시 | RBC Capital Mkts | Outperform |
| 2021-02-17 | 개시 | Needham | Buy |
| 2020-09-29 | 개시 | JMP Securities | Mkt Outperform |
| 2020-09-21 | 개시 | Truist | Buy |
| 2019-12-18 | 개시 | B. Riley FBR | Buy |
| 2019-03-26 | 재확인 | H.C. Wainwright | Buy |
| 2018-12-06 | 개시 | ROTH Capital | Buy |
| 2017-09-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-08-10 | 재확인 | Rodman & Renshaw | Buy |
| 2017-05-05 | 재확인 | Rodman & Renshaw | Buy |
| 2016-11-11 | 재확인 | FBR & Co. | Outperform |
| 2016-03-17 | 재확인 | FBR Capital | Outperform |
| 2016-03-03 | 개시 | FBR Capital | Outperform |
| 2015-11-16 | 재확인 | ROTH Capital | Neutral |
| 2015-10-29 | 재확인 | ROTH Capital | Neutral |
| 2015-05-06 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2014-12-08 | 재확인 | ROTH Capital | Buy |
| 2011-10-03 | 다운그레이드 | Maxim Group | Buy → Hold |
모두보기
CorMedix Inc 주식(CRMD)의 최신 뉴스
How The CorMedix (CRMD) Investment Story Is Shifting As Analyst Targets Reset - Yahoo Finance
How Cormedix Inc. (CRMD) Affects Rotational Strategy Timing - Stock Traders Daily
Levels Update: Can CorMedix Inc outperform under higher oil pricesWeekly Stock Analysis & Free Accurate Trade Setup Notifications - baoquankhu1.vn
CRMD News | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
Is CorMedix (CRMD) Now Offering Value After Sharp Share Price Declines? - simplywall.st
US Market Recap: What is the target price for CorMedix Inc stock2026 Stock Rankings & Daily Profit Focused Stock Screening - baoquankhu1.vn
Street Watch: Is CorMedix Inc a stock for growth or value investors2026 Momentum Check & Fast Momentum Entry Tips - baoquankhu1.vn
Aug Shorts: What makes CorMedix Inc stock attractive todayWeekly Trend Summary & Proven Capital Preservation Tips - baoquankhu1.vn
Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Long Term Gains - simplywall.st
CRMD Stock Price, Quote & Chart | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
Why did CRMD stock tumble over 11% today? - MSN
CorMedix at Citizens Life Sciences: Strategic Expansion and Growth By Investing.com - Investing.com Canada
CRMD: REZZAYO and DefenCath drive growth, with Melinta boosting revenue and new markets targeted - TradingView
CorMedix at Leerink Conference: Strategic Evolution and Market Potential By Investing.com - Investing.com Nigeria
Cormedix Earnings Call: Peak DEFENCATH, Tough Road Ahead - TipRanks
CorMedix at Leerink Conference: Strategic Evolution and Market Potential - Investing.com
CRMD: Diversified specialty pharma advancing REZZAYO and DefenCath, with strong growth catalysts ahead - TradingView
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance - Investing.com Nigeria
What is CorMedix Inc.’s book value per shareMarket Weekly Review & Fast Moving Stock Trade Plans - baoquankhu1.vn
Strength Seen in CorMedix (CRMD): Can Its 21.7% Jump Turn into More Strength? - MSN
CorMedix (CRMD) Is Down 9.4% After Reaffirming 2026 Guidance and Reporting Profit SwingWhat's Changed - simplywall.st
CorMedix Q4 2025 earnings preview - MSN
CorMedix outlines $300M–$320M revenue and $100M–$125M EBITDA targets for 2026 amid DefenCath transition and Melinta integration - MSN
CorMedix nears an 11-month low after earnings miss - MSN
CorMedix (CRMD) lags Q4 earnings estimates - MSN
CorMedix Therapeutics 2026: Portfolio Expansion, Financial Highlights, DefenCath Launch & Growth Pipeline in Specialty Pharma 1234567 - Minichart
CorMedix Strikes $300M Deal For Melinta Therapeutics, Retail Calls It A ‘Wonderful Acquisition’ - MSN
CorMedix Inc. (CRMD) Acquires Melinta Therapeutics to Expand Hospital-Focused Portfolio - MSN
Leerink cuts CorMedix stock price target on expense adjustments - Investing.com India
Update Recap: What is the target price for CorMedix Inc stockWeekly Risk Report & Real-Time Market Sentiment Reports - baoquankhu1.vn
CorMedix 2025 Financial Results: $163.1M Profit, $311.7M RevenueNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
CorMedix Reaffirms DefenCath 2027 Sales and Outlook - TipRanks
Leerink cuts CorMedix stock price target on expense adjustments By Investing.com - Investing.com South Africa
Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Growth Expectations - Yahoo Finance
CorMedix Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
CorMedix Inc. (NASDAQ:CRMD) Q4 2025 Earnings Call Transcript - Insider Monkey
Cormedix Earnings Review: Q4 Summary - Sahm
CorMedix Buyback And REZZAYO Data Shape Valuation And Risk Profile - Yahoo Finance
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance By Investing.com - Investing.com Canada
CorMedix Q4 Revenue Improves; Reaffirms FY26 Outlook; Plans To Report Phase III REZZAYO Data In Q2 - Nasdaq
Truist reiterates CorMedix stock rating on steady guidance - Investing.com India
Truist reiterates CorMedix stock rating on steady guidance By Investing.com - Investing.com South Africa
CorMedix (CRMD) Q4 2025 Earnings Call Transcript - AOL.com
CorMedix (CRMD) Valuation Check After Recent Share Price Swings And Melinta Acquisition Narrative - simplywall.st
Why Did CRMD Stock Tumble Over 11% Today? - Stocktwits
CorMedix Shares Fall After Q4 Profit Miss - marketscreener.com
CorMedix stock drops after earnings: is this dip a buy before key catalyst? - TradingView
CorMedix: Fourth Quarter Financial Results Overview - Bitget
CorMedix stock falls after earnings miss (CRMD:NASDAQ) - Seeking Alpha
Earnings call transcript: CorMedix Q4 2025 results miss EPS, stock dips - Investing.com Nigeria
Cormedix Stock Pre-Market (+6.2%) : Technical Move Ahead of Key Q2 Catalyst - Trefis
CorMedix Inc (CRMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.99%
3.03%
자본화:
|
볼륨(24시간):